Grupo del Hospital Universitario y Politécnico de La Fe (Valencia)
null Grupo del Hospital Universitario y Politécnico de La Fe (Valencia)
The Unit of Infectious Diseases at La Fe University Hospital was set up in 1998, under the leadership of José López Aldeguer. We are integrated in Spanish AIDS Research Network (RIS) since its inception. We cooperate with other national and international research groups. Our Unit has focused on clinical research. Our main areas of interest and research are the following:
- Epidemiology: To know the epidemiology of the epidemic of HIV infection in our environment over time.
- Antiretroviral treatment: We have participated in numerous clinical trials and studies focused on evaluating the efficacy and tolerability of antiretroviral treatment, both new drugs and new treatment strategies. This has allowed us to participate in research that has changed the paradigm of antiretroviral treatment throughout its history. At present we are included in studies in naïve and pre-treated patients who try out bi-therapies strategies with the goal of keeping the efficacy rates of current treatment standards lowering toxicity.
- Analysis of comorbidities in the HIV patient: We have been particularly interested in the appearance of comorbidities associated with aging related to the increase in survival in recent years. Analyzing the impact that comorbidities have on the emergence of relevant interactions with antiretroviral treatment, the associated polypharmacy, the impact on the quality of life and on the associated morbi-mortality. This has led us to the analysis of strategies for prevention and follow-up of the most prevalent comorbidities in the HIV-infected patient.
- Co-infection with hepatitis C: A high percentage of patients treated in our Unit over the years have been co-infected with HCV, this has allowed us to analyze the epidemiological, clinical and response characteristics of the treatment. We have given special attention to the appearance of complications associated with chronic liver disease in the HIV patient. Participating in national studies of hepatocellular carcinoma in this population as well as implementation and response to treatment based on direct action antivirals free of interferon.